Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines
暂无分享,去创建一个
H. Higuchi | N. Nakamura | A. Kotani | K. Imadome | Y. Kikuti | R. Kotaki | Etsuko Nagashima | M. Kawashima | Yuichiro Yamamoto | Masako Takamatsu | Natsumi Kurosaki
[1] F. Bosch,et al. Repurposing dasatinib for diffuse large B cell lymphoma , 2019, Proceedings of the National Academy of Sciences.
[2] Jun Lu,et al. Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma. , 2018, Blood.
[3] J. Utikal,et al. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression , 2018, Front. Immunol..
[4] Christian Templin,et al. 40 Years on , 2017, European heart journal.
[5] Jun O. Liu,et al. Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation , 2017, Journal of Virology.
[6] Z. Yao,et al. LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required , 2017, Oncogene.
[7] Juan F. García,et al. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS) , 2017, Histopathology.
[8] S. Tangye,et al. Human immunity against EBV—lessons from the clinic , 2017, The Journal of experimental medicine.
[9] E. Miao,et al. Programmed cell death as a defence against infection , 2017, Nature Reviews Immunology.
[10] Vijaya Subramaniam,et al. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3. , 2017, Virology.
[11] Z. Estrov,et al. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia , 2016, The Journal of Immunology.
[12] Samuel J. Taylor,et al. The targeting of human and mouse B lymphocytes by dasatinib. , 2015, Experimental hematology.
[13] A. Grañena,et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival , 2015, The Journal of pathology.
[14] Xenia Geeraerts,et al. Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies , 2014, Front. Oncol..
[15] K. Ando,et al. Clinical outcome of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era , 2014, Cancer science.
[16] S. Nimmagadda,et al. The intricate role of CXCR4 in cancer. , 2014, Advances in cancer research.
[17] Junying Yuan,et al. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death , 2013, Nature Reviews Molecular Cell Biology.
[18] Ling Wang,et al. Interferon Regulatory Factor 4 Is Activated through c-Src-Mediated Tyrosine Phosphorylation in Virus-Transformed Cells , 2013, Journal of Virology.
[19] D. Rowe,et al. The Effect of Epstein-Barr Virus Latent Membrane Protein 2 Expression on the Kinetics of Early B Cell Infection , 2013, PloS one.
[20] L. Gordon,et al. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. , 2012, Antiviral research.
[21] J. Huh,et al. Impact of the Epstein–Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea , 2012, Annals of Hematology.
[22] J. Kutok,et al. Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model , 2012, Cell.
[23] M. Rowe,et al. Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations , 2011, Herpesviridae.
[24] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[25] K. Bieging,et al. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis , 2009, Proceedings of the National Academy of Sciences.
[26] E. Vellenga,et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] N. Carragher,et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 , 2009, Molecular oncology.
[28] R. Longnecker,et al. Epstein–Barr virus LMP2A accelerates MYC-induced lymphomagenesis , 2009, Oncogene.
[29] B. Cookson,et al. Pyroptosis: host cell death and inflammation , 2009, Nature Reviews Microbiology.
[30] R. Longnecker,et al. Epstein-Barr Virus Latent Membrane Protein 2A Preferentially Signals through the Src Family Kinase Lyn , 2008, Journal of Virology.
[31] A. Beech,et al. Classification and Treatment , 2008 .
[32] A. Carbone,et al. EBV-associated lymphoproliferative disorders: classification and treatment. , 2008, The oncologist.
[33] P. De Baetselier,et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.
[34] L. Honigberg,et al. Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.
[35] L. Otterbein,et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.
[36] G. M. Taylor,et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. , 2005, Blood.
[37] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[38] L. Young,et al. Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.
[39] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[40] R. Longnecker,et al. LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. , 2001, Virology.
[41] D. Thorley-Lawson,et al. EBV Persistence Involves Strict Selection of Latently Infected B Cells1 , 2000, The Journal of Immunology.
[42] R. Longnecker,et al. Epstein-Barr Virus LMP2A-Induced B-Cell Survival in Two Unique Classes of EμLMP2A Transgenic Mice , 2000, Journal of Virology.
[43] R. Longnecker,et al. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. , 2000, Journal of virology.
[44] B. Kempkes,et al. The Proto-Oncogene c-myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2 , 1999, Journal of Virology.
[45] R. Alon,et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.
[46] V. Godfrey,et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. Thorley-Lawson,et al. EBV persistence in memory B cells in vivo. , 1998, Immunity.
[48] S. Anderson,et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.
[49] D. Thorley-Lawson,et al. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell , 1997 .
[50] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.
[51] G. Miller,et al. Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants. , 1979, Virology.